Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients

B. Haibe-Kains; C. Desmedt; A. Di Leo; E. Azambuja; D. Larsimont; J. Selleslags; S. Delaloge; C. Duhem; J. P. Kains; B. Carly; M. Maerevoet; A. Vindevoghel; G. Rouas; F. Lallemand; V. Durbecq; F. Cardoso; R. Salgado; R. Rovere; G. Bontempi; S. Michiels; M. Buyse; J. M. Nogaret; Y. Qi; F. Symmans; L. Pusztai; V. D'Hondt; M. Piccart-Gebhart; C. Sotiriou

doi:10.1016/j.gdata.2013.09.001

Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients

B. Haibe-Kains, C. Desmedt, A. Di Leo, E. Azambuja, D. Larsimont, J. Selleslags, S. Delaloge, C. Duhem, J. P. Kains, B. Carly, M. Maerevoet, A. Vindevoghel, G. Rouas, F. Lallemand, V. Durbecq, F. Cardoso, R. Salgado, R. Rovere, G. Bontempi, S. MichielsM. Buyse, J. M. Nogaret, Y. Qi, F. Symmans, L. Pusztai, V. D'Hondt, M. Piccart-Gebhart, C. Sotiriou

Pathology

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Validated biomarkers predictive of response/resistance to anthracyclines in breast cancer are currently lacking. The neoadjuvant Trial of Principle (TOP) study, in which patients with estrogen receptor (ER)-negative tumors were treated with anthracycline (epirubicin) monotherapy, was specifically designed to evaluate the predictive value of topoisomerase II-alpha (TOP2A) and develop a gene expression signature to identify those patients who do not benefit from anthracyclines. Here we describe in details the contents and quality controls for the gene expression and clinical data associated with the study published by Desmedt and colleagues in the Journal of Clinical Oncology in 2011 (Desmedt et al., 2011). We also provide R code to easily access the data and perform the quality controls and basic analyses relevant to this dataset.

Original language	English (US)
Pages (from-to)	7-10
Number of pages	4
Journal	Genomics Data
Volume	1
DOIs	https://doi.org/10.1016/j.gdata.2013.09.001
State	Published - Dec 2013

Keywords

Anthracycline
Bioinformatics
Breast cancer
Gene expression
Microarray

ASJC Scopus subject areas

Biotechnology
Biochemistry
Molecular Medicine
Genetics

Access to Document

10.1016/j.gdata.2013.09.001

Cite this

Haibe-Kains, B., Desmedt, C., Di Leo, A., Azambuja, E., Larsimont, D., Selleslags, J., Delaloge, S., Duhem, C., Kains, J. P., Carly, B., Maerevoet, M., Vindevoghel, A., Rouas, G., Lallemand, F., Durbecq, V., Cardoso, F., Salgado, R., Rovere, R., Bontempi, G., ... Sotiriou, C. (2013). Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients. Genomics Data, 1, 7-10. https://doi.org/10.1016/j.gdata.2013.09.001

Haibe-Kains, B, Desmedt, C, Di Leo, A, Azambuja, E, Larsimont, D, Selleslags, J, Delaloge, S, Duhem, C, Kains, JP, Carly, B, Maerevoet, M, Vindevoghel, A, Rouas, G, Lallemand, F, Durbecq, V, Cardoso, F, Salgado, R, Rovere, R, Bontempi, G, Michiels, S, Buyse, M, Nogaret, JM, Qi, Y , Symmans, F, Pusztai, L, D'Hondt, V, Piccart-Gebhart, M & Sotiriou, C 2013, 'Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients', Genomics Data, vol. 1, pp. 7-10. https://doi.org/10.1016/j.gdata.2013.09.001

@article{bb0d533b9e5b42ea9a996f4fa783284b,

title = "Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients",

abstract = "Validated biomarkers predictive of response/resistance to anthracyclines in breast cancer are currently lacking. The neoadjuvant Trial of Principle (TOP) study, in which patients with estrogen receptor (ER)-negative tumors were treated with anthracycline (epirubicin) monotherapy, was specifically designed to evaluate the predictive value of topoisomerase II-alpha (TOP2A) and develop a gene expression signature to identify those patients who do not benefit from anthracyclines. Here we describe in details the contents and quality controls for the gene expression and clinical data associated with the study published by Desmedt and colleagues in the Journal of Clinical Oncology in 2011 (Desmedt et al., 2011). We also provide R code to easily access the data and perform the quality controls and basic analyses relevant to this dataset.",

keywords = "Anthracycline, Bioinformatics, Breast cancer, Gene expression, Microarray",

author = "B. Haibe-Kains and C. Desmedt and {Di Leo}, A. and E. Azambuja and D. Larsimont and J. Selleslags and S. Delaloge and C. Duhem and Kains, {J. P.} and B. Carly and M. Maerevoet and A. Vindevoghel and G. Rouas and F. Lallemand and V. Durbecq and F. Cardoso and R. Salgado and R. Rovere and G. Bontempi and S. Michiels and M. Buyse and Nogaret, {J. M.} and Y. Qi and F. Symmans and L. Pusztai and V. D'Hondt and M. Piccart-Gebhart and C. Sotiriou",

year = "2013",

month = dec,

doi = "10.1016/j.gdata.2013.09.001",

language = "English (US)",

volume = "1",

pages = "7--10",

journal = "Genomics Data",

issn = "2213-5960",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients

AU - Haibe-Kains, B.

AU - Desmedt, C.

AU - Di Leo, A.

AU - Azambuja, E.

AU - Larsimont, D.

AU - Selleslags, J.

AU - Delaloge, S.

AU - Duhem, C.

AU - Kains, J. P.

AU - Carly, B.

AU - Maerevoet, M.

AU - Vindevoghel, A.

AU - Rouas, G.

AU - Lallemand, F.

AU - Durbecq, V.

AU - Cardoso, F.

AU - Salgado, R.

AU - Rovere, R.

AU - Bontempi, G.

AU - Michiels, S.

AU - Buyse, M.

AU - Nogaret, J. M.

AU - Qi, Y.

AU - Symmans, F.

AU - Pusztai, L.

AU - D'Hondt, V.

AU - Piccart-Gebhart, M.

AU - Sotiriou, C.

PY - 2013/12

Y1 - 2013/12

N2 - Validated biomarkers predictive of response/resistance to anthracyclines in breast cancer are currently lacking. The neoadjuvant Trial of Principle (TOP) study, in which patients with estrogen receptor (ER)-negative tumors were treated with anthracycline (epirubicin) monotherapy, was specifically designed to evaluate the predictive value of topoisomerase II-alpha (TOP2A) and develop a gene expression signature to identify those patients who do not benefit from anthracyclines. Here we describe in details the contents and quality controls for the gene expression and clinical data associated with the study published by Desmedt and colleagues in the Journal of Clinical Oncology in 2011 (Desmedt et al., 2011). We also provide R code to easily access the data and perform the quality controls and basic analyses relevant to this dataset.

AB - Validated biomarkers predictive of response/resistance to anthracyclines in breast cancer are currently lacking. The neoadjuvant Trial of Principle (TOP) study, in which patients with estrogen receptor (ER)-negative tumors were treated with anthracycline (epirubicin) monotherapy, was specifically designed to evaluate the predictive value of topoisomerase II-alpha (TOP2A) and develop a gene expression signature to identify those patients who do not benefit from anthracyclines. Here we describe in details the contents and quality controls for the gene expression and clinical data associated with the study published by Desmedt and colleagues in the Journal of Clinical Oncology in 2011 (Desmedt et al., 2011). We also provide R code to easily access the data and perform the quality controls and basic analyses relevant to this dataset.

KW - Anthracycline

KW - Bioinformatics

KW - Breast cancer

KW - Gene expression

KW - Microarray

UR - http://www.scopus.com/inward/record.url?scp=84892660567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892660567&partnerID=8YFLogxK

U2 - 10.1016/j.gdata.2013.09.001

DO - 10.1016/j.gdata.2013.09.001

M3 - Article

C2 - 26484051

AN - SCOPUS:84892660567

SN - 2213-5960

VL - 1

SP - 7

EP - 10

JO - Genomics Data

JF - Genomics Data

ER -

Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this